Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Danish pharmaceutical firm Novo Nordisk has signed a collaboration agreement with Sweden-based medical university Karolinska Institutet for diabetes research.
Subscribe to our email newsletter
The post-doctoral diabetes research program will be fully funded by Novo Nordisk.
In this program, a total of 12 post-doctoral researchers will be offered a three-year grant to support their research primarily within the field of diabetes and metabolism.
The research will be carried out at the Swedish university, but there will also be possibility for research exchange performed at Novo Nordisk Research and Development in Denmark.
Karolinska Institutet vice-chancellor professor Anders Hamsten said: "Novo Nordisk is the world leader in diabetes, and this initiative is of strategic importance both to them and to us.
"The agreement creates a unique opportunity for recruiting young diabetes researchers to Karolinska Institutet."
Novo Nordisk executive vice-president and chief science officer Mads Krogsgaard Thomsen said: "Together, we will train scientists in exploring basic diabetes research and translating this into new potential treatments for patients.
"Building upon the unique academic and clinical tradition at Karolinska Institutet and our company’s excellence in research and development, the collaboration holds great potential to stimulate innovation and ultimately to improve the lives of the patients."
The program will be managed by a joint steering committee with members from both the parties who will also be responsible for recruiting researchers, while the first four fellows in the program are expected to start in the autumn of 2015.
Image: Karolinska Institutet vice-chancellor Anders Hamsten and Novo Nordisk SVP Peter Kurtzhals at the signing of the agreement. Photo: Gustav Mårtensson/ Karolinska Institutet.